This is the link to the actual article. My apologies if it has...

This is the link to the actual article. My apologies if it has been submitted previously.

Jeremy R.A. Paull, Graham P. Heery, Michael D. Bobardt, Alex Castellarnau, Carolyn A. Luscombe, Jacinth K. Fairley, Philippe A. Gallay, Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro, Antiviral Research, 2021, 105089, ISSN 0166-3542, https://doi.org/10.1016/j.antiviral.2021.105089, https://www.sciencedirect.com/science/article/pii/S0166354221000796?via=ihub

Conclusions

Data from the current studies, taken together with studies of astodrimer sodium antiviral activity against HIV-1, and HSV-1 and -2, indicate that the compound exerts its antiviral activity against geographically diverse SARS-CoV-2 isolates by interfering with the early virus-cell recognition events. Astodrimer sodium is a potent virucidal agent that irreversibly reduces the infectivity of SARS-CoV-2 by >99.9% after 1 min of exposure to the virus, likely via tight binding to attachment proteins. These studies support astodrimer sodium being able to prevent early virus entry steps such as attachment, thereby reducing or preventing viral infection or cell-cell spread.
A topical antiviral agent such as astodrimer sodium that blocks binding of the virus to target cells could potentially be used against SARS-CoV-2 to augment other protective and therapeutic strategies.
The potent antiviral and irreversible virucidal activity of astodrimer sodium against SARS-CoV-2 warrants further investigation.


Funding

The research was funded by Starpharma Pty Ltd, which was responsible for study design, interpretation of data, writing the manuscript and decision to submit it.